膀胱癌分子机制及分子分型的研究进展

孔家瑾; 张璐; 郑克文

doi:10.13201/j.issn.1001-1420.2021.03.016

膀胱癌分子机制及分子分型的研究进展

- 1. 温州医科大学附属第一医院泌尿外科温州医科大学第一临床学院(浙江温州, 325000);
- 2. 中国科学院肿瘤与基础医学研究所中国科学院大学附属肿瘤医院GCP中心浙江省肿瘤医院GCP中心
基金项目:
浙江省自然科学基金(No:LQ17H050002,LQ17H300002)

详细信息

通讯作者: 郑克文,E-mail:zkw2121@163.com

中图分类号: R737.14

收稿日期: 2020-05-01

Advances in molecular mechanism and molecular subtype of bladder cancer

- 1. Department of Urology, First Affiliated Hospital of Wenzhou Medical University, First Clinical College of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China;
- 2. Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Department of GCP, Cancer Hospital of the University of Chinese Academy of Sciences, Department of GCP, Zhejiang Cancer Hospital

More Information

Corresponding author: ZHENG Kewen, E-mail: zkw2121@163.com

Received Date: 01 May 2020

摘要

摘要: 膀胱癌是世界上最常见的癌症之一。研究表明膀胱癌是一组具有不同临床病程和不同治疗反应的分子异质性疾病,其发生发展与多条分子通路相关。利用分子生物学技术对膀胱癌进行分子分型有望提高疾病的诊治水平。本文综述了近年来膀胱癌分子病理学和膀胱癌分子亚型分类的研究进展。
- 膀胱癌 /
- 分子分型 /
- 分子通路 /
- 突变谱
Abstract: Bladder cancer is one of the most common cancers in the world. Studies have shown that bladder cancer is a group of molecular heterogeneous diseases with different clinical courses and treatment responses, and its occurrence and development are related to multiple molecular pathways. Molecular classification of bladder cancer by molecular biology is expected to improve the diagnosis and treatment of the disease. This paper reviews the recent advances in molecular pathology and subtype classification of bladder cancer.
- bladder cancer /
- molecular subtype /
- molecular pathway /
- mutation spectrum

HTML全文

参考文献(23)

[1]	王猛,滕晓东.肌层浸润性膀胱癌的分子分型研究进展[J].中华病理学杂志,2017,46(6):439-442.
[2]	Al-Ahmadie H,Netto GJ.Updates on the Genomics of Bladder Cancer and Novel Molecular Taxonomy[J].Adv Anat Pathol,2020,27(1):36-43.
[3]	Jalanko T,de Jong JJ,Gibb EA,et al.Correction to:Genomic Subtyping in Bladder Cancer[J].Curr Urol Rep,2020,21(7):25.
[4]	Teo MY,Seier K,Ostrovnaya I,et al.Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers[J].J Clin Oncol,2018,36(17):1685-1694.
[5]	Mouw KW,D'Andrea AD.DNA Repair Deficiency and Immunotherapy Response[J].J Clin Oncol,2018,36(17):1710-1713.
[6]	郭园园,刘贝贝,汪盛,等.分子标记物预测肌层浸润性膀胱癌疗效的研究进展[J].临床泌尿外科杂志,2019,34(5):404-408.
[7]	Yousef PG,Gabril MY.An update on the molecular pathology of urinary bladder tumors[J].Pathol Res Pract,2018,214(1):1-6.
[8]	Robertson AG,Kim J,Al-Ahmadie H,et al.Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer[J].Cell,2017,171(3):540-556.e25.
[9]	Zhuang X,Lv M,Zhong Z,et al.Interplay between intergrin-linked kinase and ribonuclease inhibitor affects growth and metastasis of bladder cancer through signaling ILK pathways[J].J Exp Clin Cancer Res,2016,35(1):130.
[10]	Cui X,Shen D,Kong C,et al.NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo[J].Sci Rep,2017,7:40723.
[11]	Hedegaard J,Lamy P,Nordentoft I,et al.Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma[J].Cancer Cell,2016,30(1):27-42.
[12]	van Kessel K,van der Keur KA,Dyrskjot L,et al.Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups[J].Clin Cancer Res,2018,24(7):1586-1593.
[13]	Damrauer JS,Hoadley KA,Chism DD,et al.Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology[J].Proc Natl Acad Sci U S A,2014,111(8):3110-3115.
[14]	Choi W,Porten S,Kim S,et al.Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy[J].Cancer Cell,2014,25(2):152-165.
[15]	曹煜东,杜鹏.肌层浸润性膀胱癌分子分型的研究进展[J].中华泌尿外科杂志,2019,40(6):477-480.
[16]	Zhu S,Yu W,Yang X,et al.Traditional Classification and Novel Subtyping Systems for Bladder Cancer[J].Front Oncol,2020,10:102.
[17]	Li H,Zhang Q,Shuman L,et al.Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes[J].Sci Rep,2020,10(1):1439.
[18]	Inamura K.Bladder Cancer:New Insights into Its Molecular Pathology[J].Cancers(Basel),2018,10(4):100.
[19]	Sjodahl G,Lauss M,Lovgren K,et al.A molecular taxonomy for urothelial carcinoma[J].Clin Cancer Res,2012,18(12):3377-3386.
[20]	Tan TZ,Rouanne M,Tan KT,et al.Molecular Subtypes of Urothelial Bladder Cancer:Results from a Meta-cohort Analysis of 2411 Tumors[J].Eur Urol,2019,75(3):423-432.
[21]	Seiler R,Ashab H,Erho N,et al.Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy[J].Eur Urol,2017,72(4):544-554.
[22]	Seiler R,Gibb EA,Wang NQ,et al.Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer[J].Clin Cancer Res,2019,25(16):5082-5093.
[23]	Kamoun A,de Reyniès A,Allory Y,et al.A Consensus Molecular Classification of Muscle-invasive Bladder Cancer[J].Eur Urol,2020,77(4):420-433.